William Blair analyst Myles Minter has reiterated their bullish stance on SLN stock, giving a Buy rating on February 25.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Myles Minter has given his Buy rating due to a combination of factors tied to Silence’s pipeline resilience and upcoming catalysts. He views the recent share weakness—following AstraZeneca’s decision to return SLN312 rights—as driven more by macro pressures and partner reprioritization than by any fundamental setback, noting SLN312 showed competitive Phase I dyslipidemia data.
He remains confident in divesiran heading into the Phase II SANRECO readout in polycythemia vera, where he believes the agent compares favorably with other Tmprss6 approaches and with rusfertide despite its priority review. In addition, he highlights strategic upside from zerlasiran pending Lp(a)HORIZON results, and sees further validation potential from forthcoming SLN312 data versus Eli Lilly’s solbinsiran, all supporting an Outperform stance despite the loss of AstraZeneca funding.
Minter covers the Healthcare sector, focusing on stocks such as Immunic, Moderna, and Dianthus Therapeutics. According to TipRanks, Minter has an average return of 31.3% and a 59.57% success rate on recommended stocks.
In another report released on February 25, H.C. Wainwright also reiterated a Buy rating on the stock with a $75.00 price target.